Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CCR3 | P51677 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6323738 | 0.84 | REN (0.46) | CYP3A4TSHRCCR3CYP2D6CYP2C9 | |
| SCHEMBL9551243 | 0.80 | KMT2A (0.51) | CYP3A4TSHRCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL22316481 | 0.77 | NAAA (0.55) | CYP3A4TSHRCYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3648776 | 0.76 | CYP1A2 (0.52) | KMT2A | |
| SCHEMBL2235914 | 0.76 | NAAA (0.57) | CYP2D6CYP2C9CYP2C19KMT2A | |
| SCHEMBL2235923 | 0.76 | NAAA (0.57) | CYP2D6CYP2C9CYP2C19KMT2A | |
| SCHEMBL5600745 | 0.76 | CCR3 (0.56) | CYP3A4TSHRCCR3 | |
| SCHEMBL5600734 | 0.76 | CCR3 (0.56) | CYP3A4TSHRCCR3 | |
| SCHEMBL5286587 | 0.75 | EPOR (0.44) | KMT2ATMEM97SIGMAR1 | |
| SCHEMBL6950840 | 0.75 | HPGD (0.47) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030055261-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055261-A1 | Compounds with growth hormone releasing properties | GHRHR, GHSR, IGFBP1 | CYP3A4 3623/4885TSHR 63/4885CCR3 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.